Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair

Molecular Therapy

Volumn 18, Issue 9, 2010, Pages 1599-1605

  Hingorani, Mohan ^a   White, Christine L ^a   Zaidi, Shane ^a   Pandha, Hardev S ^b   Melcher, Alan A ^c   Bhide, Shreerang A ^d   Nutting, Christopher M ^d   Syrigos, Konstantinos N ^d   Vile, Richard G ^e   Vassaux, Georges ^f   Harrington, Kevin J ^d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e MAYO CLINIC   (United States)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; IODINE 131; KU 0055993; KU 0057788; KU 0060648; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; SODIUM IODIDE SYMPORTER; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CLONOGENIC ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ATAXIA TELANGIECTASIA; MUS;

EID: 77956268881     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.120     Document Type: Article

References (24)

1. Dohan, O, De la Vieja, A, Paroder, V, Riedel, C, Artani, M, Reed, M et al. (2003). The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24: 48-77.
2. Haq, M and Harmer, C (2004). Thyroid cancer: an overview. Nucl Med Commun 25: 861-867.
3. Mandell, RB, Mandell, LZ and Link, CJ Jr (1999). Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59: 661-668.
4. Boland, A, Ricard, M, Opolon, P, Bidart, JM, Yeh, P, Filetti, S et al. (2000). Adenovirusmediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60: 3484-3492.
5. Nakamoto, Y, Saga, T, Misaki, T, Kobayashi, H, Sato, N, Ishimori, T et al. (2000). Establishment and characterization of a breast cancer cell line expressing Na+/Isymporters for radioiodide concentrator gene therapy. J Nucl Med 41: 1898-1904.
6. Faivre, J, Clerc, J, Gerolami, R, Herve, J, Longuet, M, Liu, B et al. (2004). Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res 64: 8045-8051.
7. Gaut, AW, Niu, G, Krager, KJ, Graham, MM, Trask, DK and Domann, FE (2004). Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS). Head Neck 26: 265-271.
8. Cengic, N, Baker, CH, Schutz, M, Goke, B, Morris, JC and Spitzweg, C (2005). A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 90: 4457-4464.
9. Scholz, IV, Cengic, N, Baker, CH, Harrington, KJ, Maletz, K, Bergert, ER et al. (2005). Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 12: 272-280.
10. Dwyer, RM, Bergert, ER, Oconnor, MK, Gendler, SJ and Morris, JC (2005). In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 11: 1483-1489.
11. Willhauck, MJ, Sharif Samani, BR, Klutz, K, Cengic, N, Wolf, I, Mohr, L et al. (2008). Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 15: 214-223.
12. Msaouel, P, Dispenzieri, A and Galanis, E (2009). Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 11: 43-53.
13. Barton, KN, Stricker, H, Brown, SL, Elshaikh, M, Aref, I, Lu, M et al. (2008). Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 16: 1761-1769.
14. Hingorani, M, White, CL, Agrawal, VK, Vidal, L, Melcher, A and Harrington, KJ (2007). Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting- Curr Cancer Drug Targets 7: 389-409.
15. Harrington, KJ, Melcher, A, Vassaux, G, Pandha, HS and Vile, RG (2008). Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 10: 362-370.
16. Hingorani, M, White, CL, Zaidi, S, Merron, A, Peerlinck, I, Gore, ME et al. (2008). Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res 14: 4915-4924.
17. Hingorani, M, White, CL, Merron, A, Peerlinck, I, Gore, ME, Slade, A et al. (2008). Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res 68: 9771-9778.
18. Willhauck, MJ, Sharif Samani, BR, Gildehaus, FJ, Wolf, I, Senekowitsch-Schmidtke, R, Stark, HJ et al. (2007). Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 92: 4451-4458.
19. Carlin, S, Akabani, G and Zalutsky, MR (2003). In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J Nucl Med 44: 1827-1838.
20. Petrich, T, Quintanilla-Martinez, L, Korkmaz, Z, Samson, E, Helmeke, HJ, Meyer, GJ et al. (2006). Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin Cancer Res 12: 1342-1348.
21. Groot-Wassink, T, Aboagye, EO, Wang, Y, Lemoine, NR, Keith, WN and Vassaux, G (2004). Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 64: 4906-4911.
22. Farmer, H, McCabe, N, Lord, CJ, Tutt, AN, Johnson, DA, Richardson, TB et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
23. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. 2004 Identification and characterization of a novel and specific inhibitor of the ataxiatelangiectasia mutated kinase ATM Cancer Res 64 9152-9159
24. Zhao, Y, Thomas, HD, Batey, MA, Cowell, IG, Richardson, CJ, Griffin, RJ et al. (2006). Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66: 5354-5362.